These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.
    Author: Tsochatzis EA, Germani G, Burroughs AK.
    Journal: Semin Oncol; 2010 Apr; 37(2):89-93. PubMed ID: 20494700.
    Abstract:
    Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transarterial radioembolization. While transarterial therapy is now a validated treatment for unresectable HCC, there is still controversy as to which type is the optimal procedure. This is mainly due to the lack of standardization. Combining local therapies or IA therapies with systemic targeted therapies might prove more effective strategies in the future. In this article, we review transarterial therapies and critically comment on their clinical applications.
    [Abstract] [Full Text] [Related] [New Search]